Mounjaro on Gesy covers severe obesity in Cyprus with weight loss targets and a two year limit

Cyprus began paying for Mounjaro for some adults with obesity on October 15, making it one of the few public systems in Europe to cover tirzepatide for weight loss. Mounjaro on Gesy, the national health system, now comes with strict entry rules, weight loss targets and a two year limit. The drug was added to the Health Insurance Organisation's official medicines list, replacing case by case applications. It also stays covered for type 2 diabetes, though a new protocol now makes Ozempic the first choice for that condition.

Who qualifies for obesity treatment

The new protocol creates two groups of adults who can get the drug for obesity, Sigmalive reported. The first group is people with a body mass index of 40 or more. The second is people with a BMI from 35 up to 40 who also have established atherosclerotic cardiovascular disease, moderate to severe obstructive sleep apnoea, or both. In each case the treating doctor submits a pre approval request through the Gesy computer system, with the medical documents and test results the protocol requires. The request is checked against the approved criteria, so cover is not automatic. Only certain doctors can prescribe: specialists in endocrinology, internal medicine and geriatrics, plus designated general practitioners for adults, according to the Cyprus Mail. Reports did not say what share of the cost, if any, patients will pay.

Staying on the drug depends on results. Sofia Petridou, an official at the Health Insurance Organisation, told the newspaper Phileleftheros that patients must lose at least 5% of their starting weight in the first six months and at least 10% by the end of the first year. Each step needs a new assessment. Obesity treatment can be paid for up to two years in total, as long as the patient keeps meeting the criteria. Petridou said people already approved through the committee that handles individual medicine requests do not need to do anything now, and their approvals stay valid until they expire. Requests still waiting for a decision will move to the new process on their own, without a new application.

How Mounjaro on Gesy reaches patients

The route to the pharmacy counter is narrow for now. Mounjaro will be dispensed only through state hospital pharmacies until further notice, Sigmalive reported, while Ozempic stays available from private pharmacies with an electronic pre approval. That split matters for people outside the main towns, who may have to travel to a hospital pharmacy for each supply. It also gives the health system tight control over who receives the drug and how much is used, at a time when demand for weight loss injections is high. Reports did not give a date for moving Mounjaro to private pharmacies. Patients should ask their prescriber which hospital pharmacy will fill the prescription and how often they will need to collect it.

That split matters for people outside the main towns, who may have to travel to a hospital pharmacy for each supply.

The same day brought a revised protocol for Ozempic, which contains semaglutide, for type 2 diabetes. Under the updated guidance, Ozempic is now the first choice between the two drugs for people with type 2 diabetes, whatever their weight, the Cyprus Mail reported. Mounjaro is still covered for diabetes, but the guidance points doctors to Ozempic first. Both drugs still need a pre approval request through the system. For people who used to get one or the other through individual applications, the change replaces a slow, case by case route with fixed rules. Whether that speeds up access will depend on how quickly requests are assessed and on supply at the hospital pharmacies, which no report has yet described.

How Cyprus compares with other countries

Public cover for weight loss drugs remains patchy across Europe. Belgium's health minister has decided that the public insurer will not pay for Mounjaro when it is used for obesity, while keeping diabetes cover. France began partial reimbursement of Wegovy and Mounjaro in June for people meeting strict criteria. In England, a committee of MPs has called the NHS rollout of Mounjaro too slow and unambitious, saying most eligible people pay privately. Against that background, Mounjaro on Gesy offers a defined path for a small, high risk group rather than broad access. The BMI threshold of 40, or 35 with serious conditions, is close to the stricter criteria seen elsewhere.

The weight loss targets are the most unusual part of the Cypriot rules. Many public systems ask doctors to stop treatment if a patient does not respond, but the 5% and 10% thresholds here are written into the payment rules, with a firm two year limit. That design protects the budget but leaves open what happens to patients at the end of cover. Studies of these drugs have found that weight often returns after treatment stops, a point Cypriot doctors also raised in local reports. Patients who reach the two year limit may face a choice between paying privately and stopping. The rules as reported do not say whether any later course of treatment would be allowed, or on what terms.

What patients in Cyprus should do now

People who think they qualify should start with their own doctor, who can refer them to a specialist allowed to prescribe. They will need records that show their BMI and any heart disease or sleep apnoea, such as cardiology letters or a sleep study. Anyone already approved through the individual applications committee does not need to reapply now, according to the Health Insurance Organisation official quoted by Sigmalive. People with type 2 diabetes who now take Mounjaro should ask their doctor how the new first choice rule for Ozempic affects them when their current approval ends. Patients should not switch, stop or change treatment on their own, and should report side effects to their prescriber.

The change does not affect private prescriptions, which remain open to anyone a doctor judges suitable and who pays the full price. For people below the new thresholds, that private route is still the only one, and its cost is not set by Gesy. Patients should get these medicines only through a licensed pharmacy with a prescription, because counterfeit and unlicensed products are sold online in many countries. Readers who want to understand why the same pen can cost very different amounts in different systems can see our explainer on list, net, cash and copay prices. The Health Insurance Organisation has not said how many people it expects to treat under the new protocol.

Conclusion

Mounjaro on Gesy is now a real option for Cypriot adults with severe obesity, but only for those who meet a high BMI bar, pass pre approval, lose at least 5% in six months and 10% in a year, and collect the drug from a state hospital pharmacy. Cover ends after two years. For type 2 diabetes, Ozempic is now the first choice. Patients should talk to their doctor before changing anything.